Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by wildbird1on Oct 25, 2023 8:52am
357 Views
Post# 35699672

Welcome aboard...

Welcome aboard...Lucky newcomers...
For me the latest SP movement is an exchange of shares from peoples that want out to peoples that want in.
For the newcomers that did get in, here is a quote from the latest TLT-Presentation that resume very well what you did get for your money.

Date 10-23-2023.
https://theralase.com/wp-content/uploads/2023/10/Theralase-Corporate-Presentation-LIFE-Financing-10-23-2023.pdf

Page 19, paragraph 4...
TLT said " Interim data to date trending better than FDA approved Keytruda(Pembrolizumab) (61.7% improvement in CR and 90.5% improvement in duration of CR) an Adstiladrin (27.5% improvement in CR and 53.2% improvement in duration of CR)".

Although I don't like to compare Adstiladrin to Ruvidar because of it's very big immunodeficient restriction, nevertheless Adstiladrin did get the FDA BTD approval even with this big restriction.

With much better numbers TLT-Ruvidar has no restrictions whatsoever(that is huge).

Read the highlighted paragraph a few time, and you will understand why you just made a very good investment.

Welcome aboard.

<< Previous
Bullboard Posts
Next >>